Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2023
First quarter (January-March 2023) · Operating profit/loss totaled SEK -2,265,857 (-4,741,051). · Loss for the period totaled SEK -2,266,329 (-4,754,615). · Cash flow from operating activities totaled SEK -2,035,828 (-5,333,226). · Earnings per share before dilution totaled SEK -0.11 (-0,24). Earnings per share after dilution amounted to SEK - 0.11 (-0,24). Key events during the first quarter · Elicera continues Phase I/IIa trial with oncolytic virus as planned, following safety review in cohort 3. · Elicera submits Clinical Trial Application to evaluate its